GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cybin Inc (FRA:R7E1) » Definitions » Interest Coverage

Cybin (FRA:R7E1) Interest Coverage : N/A (As of Dec. 2023)


View and export this data going back to 2020. Start your Free Trial

What is Cybin Interest Coverage?

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income by its Interest Expense. Cybin's Operating Income for the three months ended in Dec. 2023 was €-18.47 Mil. Cybin's Interest Expense for the three months ended in Dec. 2023 was €0.00 Mil. GuruFocus does not calculate 's interest coverage with the available data. The higher the ratio, the stronger the company's financial strength is.

Good Sign:

Ben Graham prefers companies' interest coverage to be at least 5. Cybin Inc has enough cash to cover all of its debt. Its financial situation is stable.

(1) Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

The historical rank and industry rank for Cybin's Interest Coverage or its related term are showing as below:


FRA:R7E1's Interest Coverage is not ranked *
in the Biotechnology industry.
Industry Median: 144.99
* Ranked among companies with meaningful Interest Coverage only.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.


Cybin Interest Coverage Historical Data

The historical data trend for Cybin's Interest Coverage can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Cybin Interest Coverage Chart

Cybin Annual Data
Trend Mar20 Mar21 Mar22 Mar23
Interest Coverage
No Debt - No Debt No Debt

Cybin Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Interest Coverage Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only No Debt No Debt No Debt No Debt N/A

Competitive Comparison of Cybin's Interest Coverage

For the Biotechnology subindustry, Cybin's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cybin's Interest Coverage Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cybin's Interest Coverage distribution charts can be found below:

* The bar in red indicates where Cybin's Interest Coverage falls into.



Cybin Interest Coverage Calculation

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:

If Interest Expense is negative and Operating Income is positive, then

Interest Coverage=-1* Operating Income /Interest Expense

Else if Interest Expense is negative and Operating Income is negative, then

The company did not have earnings to cover the interest expense.

Else if Interest Expense is 0 and Long-Term Debt & Capital Lease Obligation is 0, then

The company had no debt (1).


Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Cybin's Interest Coverage for the fiscal year that ended in Mar. 2023 is calculated as

Here, for the fiscal year that ended in Mar. 2023, Cybin's Interest Expense was €0.00 Mil. Its Operating Income was €-35.17 Mil. And its Long-Term Debt & Capital Lease Obligation was €0.00 Mil.

Cybin had no debt (1).

Cybin's Interest Coverage for the quarter that ended in Dec. 2023 is calculated as

Here, for the three months ended in Dec. 2023, Cybin's Interest Expense was €0.00 Mil. Its Operating Income was €-18.47 Mil. And its Long-Term Debt & Capital Lease Obligation was €0.03 Mil.

GuruFocus does not calculate Cybin's interest coverage with the available data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The higher the ratio, the stronger the company's Financial Strength is.


Cybin  (FRA:R7E1) Interest Coverage Explanation

Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.

Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .


Cybin Interest Coverage Related Terms

Thank you for viewing the detailed overview of Cybin's Interest Coverage provided by GuruFocus.com. Please click on the following links to see related term pages.


Cybin (FRA:R7E1) Business Description

Traded in Other Exchanges
Address
100 King Street West, Suite 5600, Toronto, ON, CAN, M5X 1C9
Cybin Inc is a biopharmaceutical company involved in creating safe and effective therapeutics for patients to address a multitude of mental health issues. The company is focused on advancing psychedelic-based therapies, delivery mechanisms, novel compounds and protocols as potential treatments for various psychiatric and neurological conditions.

Cybin (FRA:R7E1) Headlines

No Headlines